AstraZeneca (STU:ZEG) FFO


STU:ZEG AstraZeneca PLC STU:ZEG
88 GF Score
Price €169.20
GF Value €157.34
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is AstraZeneca FFO?

FFO (Funds from operations) only applies to REITs.

STU:ZEG
88GF Score
AstraZeneca PLC STU:ZEG
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (STU:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued. The current stock price of €169.20 is trading 7.5% above its estimated GF Value™ of €157.34. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for STU:ZEG:

  • FFO:
  • GF Value™: €157.34 vs. price of €169.20 (7.5% above fair value)
  • GF Score™: 88/100 with 5 warning signs

No single metric tells the full story. See the STU:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for STU:ZEG

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€169.20
Price
€157.34
GF Value